Acute Lymphoblastic Leukemia Market

Acute Lymphoblastic Leukemia Market (Type - B-cell, T-cell; Treatment - Chemotherapy, Radiation Therapy, Bone Marrow Transplant, Targeted Therapy, Immunotherapy; End user - Hospital, Clinics) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

  • Rep Id : TMRGL22886
  • Published On : Jan 2019
  • No. of Pages : 184
  • Category : Pharmaceutical

1. Preface 
     1.1. Report Scope and Market Segmentation 
     1.2. Research Highlights

2. Assumptions and Research Methodology 
     2.1. Assumptions and Acronyms Used
     2.2. Research Methodology

3. Executive Summary

4. Market Overview
     4.1. Introduction
     4.2. Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, 2016–2026 
     4.3. Global Acute Lymphoblastic Leukemia Market Outlook
     4.4. Key Industry Developments

5. Market Dynamics
     5.1. Drivers and Restraints Snapshot Analysis
     5.2. Drivers
     5.3. Restraints
     5.4. Opportunities
     5.5. Key Trends

6. Global Acute Lymphoblastic Leukemia Market, by Type
     6.1. Introduction 
     6.2. Global Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Type
     6.3. Global Acute Lymphoblastic Leukemia Market Value Forecast, by Type
     6.4. Global Acute Lymphoblastic Leukemia Market Analysis, by Type
            6.4.1. B-cell
            6.4.2. T-cell

7. Global Acute Lymphoblastic Leukemia Market, by Treatment
     7.1. Key Findings 
     7.2. Introduction 
     7.3. Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by Treatment 
     7.4. Global Acute Lymphoblastic Leukemia Market Forecast, Treatment
     7.5. Global Acute Lymphoblastic Leukemia Market Analysis, by Treatment
            7.5.1. Chemotherapy
            7.5.2. Radiation Therapy
            7.5.3. Bone Marrow Transplant
            7.5.4. Targeted Therapy
            7.5.5. Immunotherapy
     7.6. Global Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Treatment

8. Global Acute Lymphoblastic Leukemia Market, by End-user
     8.1. Key Findings 
     8.2. Introduction
     8.3. Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user 
     8.4. Global Acute Lymphoblastic Leukemia Market Forecast, by End-user
     8.5. Global Acute Lymphoblastic Leukemia Market Analysis, by End-user
            8.5.1. Hospitals
            8.5.2. Clinics
            8.5.3. Others
     8.6. Global Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user

9. Acute Lymphoblastic Leukemia Market Analysis, by Region
     9.1. Key Findings
     9.2. Global Market Scenario
     9.3. Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by Region
     9.4. Global Acute Lymphoblastic Leukemia Market Forecast, by Region
            9.4.1. North America
            9.4.2. Europe
            9.4.3. Asia Pacific
            9.4.4. Latin America
            9.4.5. Middle East & Africa
     9.5. Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Region

10. North America Acute Lymphoblastic Leukemia Market
     10.1. Key Findings
     10.2. North America Acute Lymphoblastic Leukemia Market Overview
     10.3. North America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country
     10.4. North America Acute Lymphoblastic Leukemia Market Value Forecast, by Country
            10.4.1. U.S.
            10.4.2. Canada
     10.5. North America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Type
     10.6. North America Acute Lymphoblastic Leukemia Market Value Forecast, by Type
            10.6.1. B-cell
            10.6.2. T-cell
     10.7. North America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
     10.8. North America Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
            10.8.1. Chemotherapy
            10.8.2. Radiation Therapy
            10.8.3. Bone Marrow Transplant
            10.8.4. Targeted Therapy
            10.8.5. Immunotherapy
     10.9. North America Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
     10.10. North America Acute Lymphoblastic Leukemia Market Forecast, End-user
            10.10.1. Hospitals
            10.10.2. Clinics
            10.10.3. Others
     10.11. North America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user

11. Europe Acute Lymphoblastic Leukemia Market
     11.1. Key Findings
     11.2. Europe Acute Lymphoblastic Leukemia Market Overview
     11.3. Europe Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country/Sub-region
     11.4. Europe Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
            11.4.1. Germany
            11.4.2. U.K.
            11.4.3. France
            11.4.4. Spain
            11.4.5. Italy
            11.4.6. Rest of Europe
     11.5. Europe Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Type
     11.6. Europe Acute Lymphoblastic Leukemia Market Value Forecast, by Type
            11.6.1. B-cell
            11.6.2. T-cell
     11.7. Europe Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
     11.8. Europe Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
            11.8.1. Chemotherapy
            11.8.2. Radiation Therapy
            11.8.3. Bone Marrow Transplant
            11.8.4. Targeted Therapy
            11.8.5. Immunotherapy
     11.9. Europe Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
     11.10. Europe Acute Lymphoblastic Leukemia Market Forecast, End-user
            11.10.1. Hospitals
            11.10.2. Clinics
            11.10.3. Others
     11.11. Europe Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user

12. Asia Pacific Acute Lymphoblastic Leukemia Market
     12.1. Key Findings
     12.2. Asia Pacific Acute Lymphoblastic Leukemia Market Overview
     12.3. Asia Pacific Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country/Sub-region
     12.4. Asia Pacific Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
            12.4.1. China
            12.4.2. Japan
            12.4.3. India
            12.4.4. Australia & New Zealand
            12.4.5. Rest of Asia Pacific
     12.5. Asia Pacific Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Type
     12.6. Asia Pacific Acute Lymphoblastic Leukemia Market Value Forecast, by Type
            12.6.1. B-cell
            12.6.2. T-cell
     12.7. Asia Pacific Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
     12.8. Asia Pacific Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
            12.8.1. Chemotherapy
            12.8.2. Radiation Therapy
            12.8.3. Bone Marrow Transplant
            12.8.4. Targeted Therapy
            12.8.5. Immunotherapy
     12.9. Asia Pacific Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
     12.10. Asia Pacific Acute Lymphoblastic Leukemia Market Forecast, End-user
            12.10.1. Hospitals
            12.10.2. Clinics
            12.10.3. Others
     12.11. Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user

13. Latin America Acute Lymphoblastic Leukemia Market
     13.1. Key Findings
     13.2. Latin America Acute Lymphoblastic Leukemia Market Overview
     13.3. Latin America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country/Sub-region
     13.4. Latin America Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
            13.4.1. Brazil
            13.4.2. Mexico
            13.4.3. Rest of Latin America
     13.5. Latin America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Type
     13.6. Latin America Acute Lymphoblastic Leukemia Market Value Forecast, by Type
            13.6.1. B-cell
            13.6.2. T-cell
     13.7. Latin America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
     13.8. Latin America Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
            13.8.1. Chemotherapy
            13.8.2. Radiation Therapy
            13.8.3. Bone Marrow Transplant
            13.8.4. Targeted Therapy
            13.8.5. Immunotherapy
     13.9. Latin America Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
     13.10. Latin America Acute Lymphoblastic Leukemia Market Forecast, End-user
            13.10.1. Hospitals
            13.10.2. Clinics
            13.10.3. Others
     13.11. Latin America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user

14. Middle East & Africa Acute Lymphoblastic Leukemia Market
     14.1. Key Findings
     14.2. Middle East & Africa Acute Lymphoblastic Leukemia Market Overview
     14.3. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country/Sub-region
     14.4. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Forecast, by Country
            14.4.1. GCC Countries
            14.4.2. Israel
            14.4.3. South Africa
            14.4.4. Rest of Middle East & Africa
     14.5. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Type
     14.6. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Forecast, by Type
            14.6.1. B-cell
            14.6.2. T-cell
     14.7. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
     14.8. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
            14.8.1. Chemotherapy
            14.8.2. Radiation Therapy
            14.8.3. Bone Marrow Transplant
            14.8.4. Targeted Therapy
            14.8.5. Immunotherapy
     14.9. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
     14.10. Middle East & Africa Acute Lymphoblastic Leukemia Market Forecast, End-user
     14.11. Hospitals
     14.12. Clinics
     14.13. Others
     14.14. Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user

15. Competition Landscape
     15.1. Acute Lymphoblastic Leukemia Market Share Analysis, by Company 
     15.2. Competition Matrix 
     15.3. Company Profile 
            15.3.1. Pfizer, Inc. 
                      15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.3.1.2. Financial Overview
                      15.3.1.3. Product Portfolio
                      15.3.1.4. SWOT Analysis
                      15.3.1.5. Strategic Overview
            15.3.2. Novartis AG 
                      15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.3.2.2. Financial Overview
                      15.3.2.3. Product Portfolio
                      15.3.2.4. SWOT Analysis
                      15.3.2.5. Strategic Overview
            15.3.3. F. Hoffmann-La Roche Ltd. 
                      15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.3.3.2. Financial Overview
                      15.3.3.3. Product Portfolio
                      15.3.3.4. SWOT Analysis
                      15.3.3.5. Strategic Overview
            15.3.4. Sanofi 
                      15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.3.4.2. Financial Overview
                      15.3.4.3. Product Portfolio
                      15.3.4.4. SWOT Analysis
                      15.3.4.5. Strategic Overview
            15.3.5. Erytech Pharma Inc. 
                      15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.3.5.2. Financial Overview
                      15.3.5.3. Product Portfolio
                      15.3.5.4. SWOT Analysis
                      15.3.5.5. Strategic Overview
            15.3.6. CELGENE CORPORATION 
                      15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.3.6.2. Financial Overview
                      15.3.6.3. Product Portfolio
                      15.3.6.4. SWOT Analysis
                      15.3.6.5. Strategic Overview
            15.3.7. Amgen, Inc.
                      15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.3.7.2. Financial Overview
                      15.3.7.3. Product Portfolio
                      15.3.7.4. SWOT Analysis
                      15.3.7.5. Strategic Overview
            15.3.8. Bristol-Myers Squibb Company 
                      15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.3.8.2. Financial Overview
                      15.3.8.3. Product Portfolio
                      15.3.8.4. SWOT Analysis
                      15.3.8.5. Strategic Overview
            15.3.9. Spectrum Pharmaceuticals, Inc. 
                      15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.3.9.2. Financial Overview
                      15.3.9.3. Product Portfolio
                      15.3.9.4. SWOT Analysis
                      15.3.9.5. Strategic Overview

List of Tables

Table 01: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 02: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016 – 2026
Table 03: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016–2026
Table 04: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 05: North America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country,
Table 06: North America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Type,
Table 07: North America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
Table 08: North America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016 – 2026
Table 09: Europe Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region,
Table 10: Europe Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Type,
Table 11: Europe Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
Table 12: Europe Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016 – 2026
Table 13: Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 14: Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Type,
Table 15: Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
Table 16: Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016 – 2026
Table 17: Latin America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region,
Table 18: Latin America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Type,
Table 19: Latin America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
Table 20: Latin America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016 – 2026
Table 21: Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 22: Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Type,
Table 23: Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
Table 24: Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user,

List of Figures

Figure 01: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, 2016–2026
Figure 02: Global Acute Lymphoblastic Leukemia Market Value Share (%), by Type (2017)
Figure 03: Global Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment (2017)
Figure 04: Global Acute Lymphoblastic Leukemia Market Value Share (%), by End-user (2017)
Figure 05: Global Acute Lymphoblastic Leukemia Market Value Share (%), by Region (2017)
Figure 06: Global Acute Lymphoblastic Leukemia Market Value Share (%), by Type, 2018 and 2026
Figure 07: Global Acute Lymphoblastic Leukemia Market Attractiveness, by Type, 2018–2026
Figure 08: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by B-cell
Figure 09: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by T-cell
Figure 10: Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by Treatment, 2018-2026
Figure 11: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Chemotherapy
Figure 12: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Radiation Therapy, 2016–2026
Figure 13: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Bone Marrow Transplant
Figure 14: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Targeted Therapy, 2016–2026
Figure 15: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Immunotherapy, 2016–2026
Figure 16: Global Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Treatment, 2018-2026
Figure 17: Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
Figure 18: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospitals
Figure 19: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Clinics, 2016–2026
Figure 20: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
Figure 21: Global Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018–2026
Figure 22: Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by Region, 2018 and 2026
Figure 23: Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Region, 2018-2026
Figure 24: North America Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 25: North America Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country, 2018 and 2026
Figure 26: North America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country, 2018–2026
Figure 27: North America Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2018 and 2026
Figure 28: North America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2018–2026
Figure 29: North America Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
Figure 30: North America Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
Figure 31: North America Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
Figure 32: North America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
Figure 33: Europe Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 34: Europe Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 35: Europe Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 36: Europe Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2018 and 2026
Figure 37: Europe Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2018–2026
Figure 38: Europe Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
Figure 39: Europe Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
Figure 40: Europe Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
Figure 41: Europe Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
Figure 42: Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 43: Asia Pacific Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 44: Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 45: Asia Pacific Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2018 and 2026
Figure 46: Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2018–2026
Figure 47: Asia Pacific Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
Figure 48: Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
Figure 49: Asia Pacific Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
Figure 50: Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
Figure 51: Latin America Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 52: Latin America Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 53: Latin America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 54: Latin America Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2018 and 2026
Figure 55: Latin America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2018–2026
Figure 56: Latin America Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
Figure 57: Latin America Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
Figure 58: Latin America Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
Figure 59: Latin America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
Figure 60: Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, 2016–2026
Figure 61: Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 62: Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 63: Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2018 and 2026
Figure 64: Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2018–2026
Figure 65: Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
Figure 66: Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
Figure 67: Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
Figure 68: Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018–2026
Figure 69: Global Acute Lymphoblastic Leukemia Market Share, by Company, 2017
Figure 70: Pfizer, Inc.’s Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 71: Pfizer, Inc.’s Oncology Business Segment Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
Figure 72: Pfizer, Inc.’s Revenue Share (%), by Business Segment, 2017
Figure 73: Pfizer, Inc.’s Revenue Share (%), by Region, 2017
Figure 74: Novartis AG’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 75: Novartis AG’s Oncology Business Segment Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2017
Figure 76: Novartis AG’s Net Sales (%), by Business Segment, 2017
Figure 77: Novartis AG’s Net Sales (%), by Region, 2017
Figure 78: F. Hoffmann-La Roche Ltd.’s, Oncology Segment, Revenue (US$ Bn), 2015–2017
Figure 79: F. Hoffmann-La Roche Ltd.’s Pharmaceutical Segment R&D Expenditure (US$ Bn), 2015–2017
Figure 80: F. Hoffmann-La Roche Ltd.’s Pharmaceutical Segment Revenue (%), by Specialty (2017)
Figure 81: F. Hoffmann-La Roche Ltd.’s Pharmaceutical Segment Revenue (%), by Region (2017)
Figure 82: Sanofi’s Revenue (US$ Bn), 2014?2017
Figure 83: Sanofi’s Regional Sales Breakdown (%), 2017
Figure 84: CELGENE CORPORATION Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 85: CELGENE CORPORATION Marketing & Sales and R&D Expenses (%), 2015–2017
Figure 86: CELGENE CORPORATION Breakdown of Net Sales (%), by Business Segment, 2017
Figure 87: CELGENE CORPORATION Breakdown of Net Sales (%), by Region, 2017
Figure 88: Amgen, Inc. Marketing & Sales and R&D Expenses (%), 2015–2017
Figure 89: Amgen, Inc. Breakdown of Net Sales (%), by Region, 2017
Figure 90: Amgen, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 91: Bristol-Myers Squibb Company Revenue (US$ Bn), 2014-2017
Figure 92: Bristol-Myers Squibb Company R&D Expenditure (US$ Bn), 2015- 2017
Figure 93: Bristol-Myers Squibb Company Revenue, by Geography, 2017
Figure 94: Spectrum Pharmaceuticals, Inc. Revenue (US$ Mn), 2015- 2017
Figure 95: Spectrum Pharmaceuticals, Inc. R&D Expenditure (US$ Mn), 2014-2017

.